Eton Pharmaceuticals (ETON) Projected to Post Quarterly Earnings on Tuesday

Eton Pharmaceuticals (NASDAQ:ETON) is projected to announce its earnings results before the market opens on Tuesday, March 18th. Analysts expect the company to announce earnings of ($0.02) per share and revenue of $10.53 million for the quarter.

Eton Pharmaceuticals Price Performance

Shares of NASDAQ ETON opened at $15.58 on Friday. Eton Pharmaceuticals has a 1 year low of $3.03 and a 1 year high of $18.41. The firm has a 50-day moving average of $15.33 and a 200 day moving average of $11.23. The stock has a market cap of $405.87 million, a P/E ratio of -70.82 and a beta of 1.37.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on ETON. Craig Hallum upped their price objective on shares of Eton Pharmaceuticals from $15.00 to $18.00 and gave the company a “buy” rating in a report on Wednesday, January 8th. B. Riley assumed coverage on shares of Eton Pharmaceuticals in a report on Friday, January 10th. They issued a “buy” rating and a $21.00 price target on the stock. Finally, HC Wainwright increased their price target on shares of Eton Pharmaceuticals from $17.00 to $33.00 and gave the stock a “buy” rating in a report on Thursday, January 23rd.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.